PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
Martina S.J. McDermott(UCLA Health), Norma O’Donovan(Dublin City University)
Cited by 42
Related Papers
Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
|Clinical Cancer Research|2023|48
Predictive biomarkers for dasatinib treatment in melanoma
|Oncoscience|2014|8